|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | 126 E Lincoln Avenue |
Address2 | P.O. Box 2000 |
| City | Rahway |
State | NJ |
Zip Code | 07065 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 24908-12
|
||||||||
|
6. House ID# 313040000
|
||||||||
| TYPE OF REPORT | 8. Year | 2024 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Bob Filippone |
Date | 4/22/2024 2:52:00 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
H.R. 3, (117th Cong.) Elijah E. Cummings Lower Drug Costs Now Act
H.R. 19, (117th Cong.) Lower Costs, More Cures Act of 2021
H.R. 830, Help Ensure Lower Patient (HELP) Copays Act
H.R. 1503/S. 2916, Prescription Information Modernization Act of 2023
H.R. 2679, Pharmacy Benefits Manager Accountability Act
H.R. 2691, Transparent Prices Required to Inform Consumer and Employers (Transparent PRICE) Act
H.R. 2816, Pharmacy Benefit Manager Sunshine and Accountability Act
H.R. 2880, Protecting Patients Against PBM Abuses Act
H.R. 2940/S. 1355, Pioneering Antimicrobial Subscriptions To End Upsurging Resistance Act (PASTEUR) Act of 2023
H.R. 3290, To amend title III of the Public Health Service Act to ensure transparency and oversight of the 340B drug discount program
H.R. 3285, Fairness for Patient Medications Act
H.R. 3633, PREVENT HPV Cancers Act of 2023
H.R. 4368/S. 2131, Agriculture, Rural Development, Food and Drug Administration, and Related Agencies Appropriations Act, 2024
H.R. 4895, Lowering Drug Costs for American Families Act
H.R. 5376/S. 2474, Share the Savings with Seniors Act
H.R. 6283, Delinking Revenue from Unfair Gouging (DRUG) Act
H.R. 7174, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program
H.R. 7635, The 340B PATIENTS Act of 2024
S. 150, Affordable Prescriptions for Patients Act of 2023
S. 1339, Pharmacy Benefit Manager Reform Act
S. 1895 (116th Congress) Lower Health Care Costs Act
S. 2333, Pandemic and All-Hazards Preparedness and Response Act
S. 2543 (116th Congress) Prescription Drug Pricing Reduction Act of 2019
Issues relating to,
340B program integrity;
340B of the Public Health Services Act;
340B issues;
340B drug pricing program;
Drug pricing;
Drug pricing and reimbursement issues;
Anti-microbial Resistance;
Cost and value of medicines;
Respiratory Syncytial Virus (RSV) immunization;
Vaccines catch up;
Vaccines issues;
Package inserts, labeling issues, and E-Labeling authorization legislation;
Pharmaceutical Supply Channel issues;
Drug shortage issues;
Inflation Reduction Act (P.L. 117-169), issues relating to drug pricing provisions;
Issues related to the Patent and Trademark Law Amendments Act (PL 96-517);
FY-2024 Budget and Appropriations Legislation;
Intellectual property protection and trade issues;
WTO Trade-Related Aspects of Intellectual Property Rights (TRIPS) Agreement;
WTO IP Waiver for COVID therapeutics
Animal Health;
Animal Health Technology Issues;
Animal Health Policy Issues: ADUFA & Funding for Electronic Animal Traceability;
One Health Issues;
General pharmaceutical issues;
Farm Bill 2023;
Vaccine Injury Compensation Program (VICP);
Diversity in clinical trials;
Accelerated approval reform;
Pharmacy Benefit Manager (PBM) policy issues;
Pharmacy Benefit Manager reforms.
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Bradley |
Rossin |
|
|
|
Liz |
Schwartz |
|
|
|
Erin |
Darling |
|
|
|
Adam |
Huftalen |
|
|
|
Bradford |
Tallamy |
|
|
|
Amelia |
Breinig |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
H.R. 1613, Drug Price Transparency in Medicaid Act of 2023
H.R. 2666, Medicaid VBPs for Patients (MVP) Act
H.R. 5376, (117th Cong.) Build Back Better Act
H.R. 7174, To amend title XI of the Social Security Act to equalize the negotiation period between small-molecule and biologic candidates under the Drug Price Negotiation Program
H.R. 7635, The 340B PATIENTS Act of 2024
S. 476 (116th Congress) Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019
Issues relating to,
Medicare;
Medicare Part B and D drug pricing issues;
340B program integrity;
340B of the Public Health Services Act;
340B drug pricing program;
Drug pricing;
Drug pricing and reimbursement issues;
FY-2024 Budget and Appropriations Legislation;
Medicaid drug rebate program (MDRP);
Medicaid Best Price Policy;
Medicaid - Centers for Medicare & Medicaid Services notice of proposed rulemaking: "Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program."
17. House(s) of Congress and Federal agencies Check if None
U.S. SENATE, U.S. HOUSE OF REPRESENTATIVES
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Bradley |
Rossin |
|
|
|
Liz |
Schwartz |
|
|
|
Erin |
Darling |
|
|
|
Adam |
Huftalen |
|
|
|
Bradford |
Tallamy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Issues relating to,
Tax reform and tax policy, generally;
Tax Cuts and Jobs Act of 2017 (P.L. 115-97);
Inflation Reduction Act (P.L. 117-169), provisions relating to budget reconciliation and taxes.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Bradley |
Rossin |
|
|
|
Liz |
Schwartz |
|
|
|
Bradford |
Tallamy |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |